NCT07008703View on ClinicalTrials.gov

Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

March 27, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Cancer Pain
Interventions
DRUG

Injection of humanized nerve growth factor (NGF) antibody

Subcutaneous injection, 20mg

Trial Locations (1)

450008

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Shenyang Sunshine Pharmaceutical Co., LTD.

INDUSTRY